Stocks / PTGX / Free Cash Flow

Protagonist Therapeutics, Inc. Free Cash Flow 2014–2025

Protagonist Therapeutics, Inc. reported $56.08M of free cash flow for fiscal 2025. That was 69.3% lower than fiscal 2024. Compared with fiscal 2020, the change was +176.9%.

Latest filed value
$56.08M
One-year change
-69.3%
Change since 2020
+176.9%
Latest period end
2025
Protagonist Therapeutics, Inc. Free Cash Flow history from 2014 to 2025FY 2014: -8042000FY 2015: -14784000FY 2016: -30319000FY 2017: 3206000FY 2018: -50433000FY 2019: -42494000FY 2020: -72955000FY 2021: -108966000FY 2022: -108932000FY 2023: -70845000FY 2024: 182797000FY 2025: 56081000
Annual filed history. Hover chart points for raw values; the accessible table below is the source of record.
Fiscal yearFree Cash FlowChange (YoY)
FY 2025$56.08M-69.3%
FY 2024$182.80M+358.0%
FY 2023$-70.84M+35.0%
FY 2022$-108.93M+0.0%
FY 2021$-108.97M-49.4%
FY 2020$-72.95M-71.7%
FY 2019$-42.49M+15.7%
FY 2018$-50.43M-1673.1%
FY 2017$3.21M+110.6%
FY 2016$-30.32M-105.1%
FY 2015$-14.78M-83.8%
FY 2014$-8.04M

Source: Protagonist Therapeutics, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PTGX 10-K filings at SEC EDGAR · Methodology · Download CSV.

How to read this history

Protagonist Therapeutics, Inc. reported $56.08M of free cash flow for fiscal 2025. That was 69.3% lower than fiscal 2024. Compared with fiscal 2020, the change was +176.9%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.

Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.

See the full picture for Protagonist Therapeutics, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Protagonist Therapeutics, Inc. — frequently asked questions

What is Protagonist Therapeutics, Inc.'s free cash flow?

Protagonist Therapeutics, Inc. (PTGX) reported free cash flow of $56.08M for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.

More PTGX financial history

Full PTGX fundamentals page → · Analyze free cash flow with a free tool → · All 1,500+ companies →